Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis
Links shared publicly online about this topic.
- 214total visits
Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis
Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).
View full resource at news-medical.net
Tags: Bronchiectasis, Antibiotic, Cipro, Ciprobay
Most Recently Shared on June 16, 2011 at 1:40 pm By:
Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis: Aradigm Corporation ... http://bit.ly/m6m5x4
Advertisement
